Schizophrenia
Schizophrenia is a chronic mental disorder that typically manifests in young adulthood, characterized by reoccurring episodes of psychosis, including auditory or visual hallucinations, delusions, disorganized thinking and behavior, and social withdrawal. Diagnosis relies on behavioral observations, psychiatric history, and reports from acquaintances, with symptoms needing to be present for at least one to six months.
Health Outcomes
- Absence of Biogenic Amines Production
- Achieved Remission
- Activation of G-Protein Coupled Receptors
- Alleviated Clinical Outcomes
- Altered Brain Activity to Negative Emotional Stimuli
- Altered Catecholamine Level
- Altered Monoamine Signaling
- Altered Neurobiological Markers
- Altered Pyridoxine Concentration
- Changed Brain Activity
- Changed Functional Connectivity
- Comparable Tolerability
- Decreased Composite Scores
- Demonstrated Long-term Safety
- Elevated Serum Acetylcholine Levels
- Enhanced Adverse Event Reporting
- Enhanced BDNF-TrkB Signaling
- Enhanced Brain-Derived Neurotrophic Factor Levels
- Enhanced Neuropharmacological Function
- Enhanced Sensory Perception
- Improved Adherence Ability
- Improved Behavioral Abnormalities
- Improved Behavioral Elements
- Improved Behavioral Health
- Improved Cognitive Behavior
- Improved Cognitive Score
- Improved Constructional Praxis
- Improved Decision Accuracy
- Improved Decision-Making Accuracy
- Improved Depressive Symptoms
- Improved Digit Symbol Substitution Test Score
- Improved Distractor Interference
- Improved Emotional Well-Being Quality of Life
- Improved Executive Function
- Improved Flexibility or Set Shift
- Improved General Behavioral Scores
- Improved Global Assessment of Efficacy
- Improved Global Clinical Impression
- Improved Global Clinical Status
- Improved Glutamate-Serine-Glycine Index
- Improved Gut-Brain Axis-Related Neuropsychiatric Health
- Improved Hippocampal Fractional Anisotropy
- Improved Inhibitory Control
- Improved Inhibitory Executive Process
- Improved MMSE Score
- Improved Medication Adherence
- Improved Mental Health
- Improved Mini-Mental State Examination Score
- Improved Negative Symptom
- Improved Negative Symptom Response Rate
- Improved Neurobehavioral Function
- Improved Neuropsychiatric Outcomes
- Improved Neurotransmitter Metabolism
- Improved Neurotransmitter Profile
- Improved Numeric Working Memory
- Improved Paired Associate Learning
- Improved Positive and Negative Syndrome Scale Total Score
- Improved Problem-Solving Skills
- Improved Psychomotor Speed
- Improved Psychosocial Domain Score
- Improved Psychosocial Health-Related Quality of Life
- Improved Reaction Time
- Improved Reaction Time on Incongruent Stroop Task
- Improved Responder Rate
- Improved Role Emotional
- Improved Schizophrenia
- Improved Set Shifting Ability
- Improved Set-Shifting
- Improved Set-Shifting Reaction Time
- Improved Significant Response Rate
- Improved Social Emotional Cognition
- Improved Social Functioning
- Improved Social Functioning Quality of Life
- Improved Socialization
- Improved Spatial Working Memory
- Improved Stroop Word Test
- Improved Synaptic Plasticity
- Improved Target-Distractor Discriminability
- Improved Therapeutic Consistency
- Improved Therapeutic Efficacy
- Improved Therapy Acceptability
- Improved Trail Making Test Time
- Improved Treatment Compliance
- Improved Verbal Episodic Memory
- Improved Verbal Fluency
- Improved Visual Surround Suppression
- Improved Visual-Spatial Function
- Improved Wechsler Memory Scale Score
- Improved Willingness to Continue Treatment
- Improved Working Memory
- Improved Working Memory Speed
- Increased 3-Hydroxykynurenine to Kynurenine Ratio
- Increased Anger/Hostility
- Increased BDNF Levels in the Prefrontal Cortex
- Increased Brain Choline Level
- Increased Brain GABA Levels
- Increased Clinical Response Proportion
- Increased Distractibility
- Increased Dopamine Transporter Binding
- Increased False Alarm Rate on Behavioral Performance Test
- Increased Folate Levels
- Increased Locomotor Activity During Active Phase
- Increased Negative Transcriptional Regulation
- Increased P3b Amplitude
- Increased Plasma Kynurenic Acid Levels
- Increased Plasma Tryptophan Concentration
- Increased Postsynaptic Density Protein 95 Levels
- Increased Prefrontal Cortex Deoxygenated Hemoglobin Level
- Increased Production of Beneficial Neurotransmitter GABA
- Increased Production of Biogenic Amines
- Increased Prolactin Level
- Increased Propionic Acid Levels
- Increased Propionic Acid Production
- Increased Serotonin 2A Receptor Levels
- Increased Serum BDNF Levels
- Increased Social Avoidance
- Modified Resting-State Brain Connectivity
- Modulated Endocannabinoid System
- Modulated Signal Transduction Pathways
- Neuroprotection Against Dopamine Neuronal Loss
- No CYP1A2 or CYP3A4 Interaction
- No Change in Appetite Parameters
- No Change in Plasma GABA Levels
- No Difference in Adverse Events
- No Significant Impact on Bacterial Community Composition or Diversity
- Normalized Neurotransmitter Levels
- Reduced Adherence Attrition
- Reduced Aggressive Feeling
- Reduced Agitation
- Reduced Anhedonia
- Reduced Anthranilic Acid Level
- Reduced Behavioral Symptoms
- Reduced Binocular Rivalry Reversal Rate
- Reduced Calgary Depression Scale for Schizophrenia Score
- Reduced Cognitive Function
- Reduced Confusion and Bewilderment
- Reduced Cortical Excitation
- Reduced Crying
- Reduced D-Tryptophan Levels
- Reduced DOPAC Levels in Amygdaloid Cortex
- Reduced Digit Vigilance Task Error
- Reduced Dopamine Levels
- Reduced Error Rate on Neutral Stroop Task
- Reduced Extrapyramidal Symptoms
- Reduced General Psychopathology
- Reduced General Psychopathology Score
- Reduced Glutamate Level
- Reduced Gut Bacteria Associated with Mental Illness
- Reduced Hippocampal Apoptosis
- Reduced Indoleamine 2,3-Dioxygenase Activity
- Reduced Interference Score on Simon Task
- Reduced Kynurenine Level
- Reduced Kynurenine-Tryptophan Ratio
- Reduced N-acetylaspartate Level
- Reduced Negative Symptom Score
- Reduced Negative Symptoms
- Reduced Omission Error
- Reduced P3b Amplitude
- Reduced Plasma LPS Levels
- Reduced Positive Symptom
- Reduced Positive Symptom Score
- Reduced Positive and Negative Syndrome Scale Negative Subscale
- Reduced Prefrontal Cortex Activation
- Reduced Prefrontal Cortex Oxygenated Hemoglobin
- Reduced Prefrontal Cortex Total Hemoglobin Level
- Reduced Psychiatric Symptom
- Reduced Psychiatric Symptom Severity
- Reduced Psychological Score
- Reduced Psychopathology Symptoms
- Reduced Psychotic Symptom Severity
- Reduced Rearing Behavior
- Reduced Relapse
- Reduced Relapse Rate
- Reduced Response Time on Flanker Task
- Reduced Serum BDNF Levels
- Reduced Serum Glutamate Levels
- Reduced Set-Shifting Reversal Error
- Reduced Simple Reaction Time
- Reduced Stroop Reaction Time
- Reduced Suicide Attempt
- Reduced Suicide Ideation
- Reduced Suicide-Related Emergency or Hospital Visit
- Reduced Suicide-Related Endpoints
- Reduced Total PANSS Score
- Reduced Total Side Effects Incidence
- Reduced Tower of London Test Completion Time
- Reduced Tower of London Test Start Time
- Reduced Trail Making Test Completion Time
- Reduced Treatment Discontinuation
- Reduced Visual Reaction Time
- Reduced Washing Solution Volume
- Reduced cFos Expression in Brain Areas
- Regulated Microglial Activation
- Regulation of Neuroactive Ligand Receptor Interaction Pathway
- Stabilized Dopamine Pathway Function
- Stable Brain Metabolite Levels
- Unchanged Risk of Sepsis
- Worsened Inhibitory Control